- Trials with a EudraCT protocol (118)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
118 result(s) found for: Lymphoid tissue.
Displaying page 1 of 6.
EudraCT Number: 2012-001768-31 | Sponsor Protocol Number: ZENO-01 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: MALT Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004289-42 | Sponsor Protocol Number: ZENO-06021957 | Start Date*: 2008-03-20 | |||||||||||
Sponsor Name:National and Kapodistrian University of Athens | |||||||||||||
Full Title: 90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
Medical condition: extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000767-41 | Sponsor Protocol Number: AGMT_MALT | Start Date*: 2008-04-30 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | |||||||||||||
Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005818-10 | Sponsor Protocol Number: AGMT_MALT-2 | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
Full Title: PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) | |||||||||||||
Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004896-38 | Sponsor Protocol Number: IELSG38 | Start Date*: 2014-02-13 | |||||||||||
Sponsor Name:IELSG (International Extranodal Lymphoma Study Group) | |||||||||||||
Full Title: A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF ... | |||||||||||||
Medical condition: Patients with MALT Lymphoma treated with chlorambucil and rituximab followed by maintenance treatment with subcutaneous rituximab | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007725-39 | Sponsor Protocol Number: MALT2008-01 | Start Date*: 2009-05-05 | |||||||||||
Sponsor Name:Fundación GEL/TAMO | |||||||||||||
Full Title: ESTUDIO MULTICENTRICO FASE II, NO ALEATORIZADO, DE RITUXIMAB EN COMBINACIÓN CON BENDAMUSTINA COMO PRIMER TRATAMIENTO SISTÉMICO EN LINFOMA DE CÉLULAS B DE LA ZONA MARGINAL EXTRAGANGLIONAR DEL TEJID... | |||||||||||||
Medical condition: Linfoma no hodgkiniano marginal de tipo MALT en una primera línea de inmunoquimioterapia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001245-14 | Sponsor Protocol Number: CC-5013-NHL-007 | Start Date*: 2013-12-13 | ||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
Full Title: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lym... | ||||||||||||||||||||||||||||
Medical condition: Relapsed/refractory indolent lymphoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) IT (Completed) PT (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004808-37 | Sponsor Protocol Number: HD-K | Start Date*: 2011-12-06 | ||||||||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | ||||||||||||||||||
Full Title: Phase II clinical study on the activity of salvage therapy with high doses of oral clarithromycin in patients with extranodal marginal zone relapsed or refractory lymphoma | ||||||||||||||||||
Medical condition: patients with extranodal marginal zone relapsed or refractory lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001521-13 | Sponsor Protocol Number: MALT-A1 | Start Date*: 2016-06-14 |
Sponsor Name:Med. Univ. Wien | ||
Full Title: A PHASE II TRIAL OF LONG-TERM TREATMENT WITH AZITHROMYCIN IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA | ||
Medical condition: MALT Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005223-32 | Sponsor Protocol Number: OMB116481 | Start Date*: 2013-08-29 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin I, Abt. Onkologie | |||||||||||||
Full Title: A Phase II trial of Ofatumumab in patients with lymphoma of the of the mucosa associated lymphoid tissue (MALT-Lymphoma) | |||||||||||||
Medical condition: LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002761-35 | Sponsor Protocol Number: LAL1811 | Start Date*: 2012-11-14 | |||||||||||
Sponsor Name:INCYTE Biosciences International Sarl | |||||||||||||
Full Title: Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio mult... | |||||||||||||
Medical condition: Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011725-14 | Sponsor Protocol Number: IELSG 34 | Start Date*: 2010-06-23 | ||||||||||||||||||||||||||
Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) | ||||||||||||||||||||||||||||
Full Title: IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14 | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory marginal zone B-cell lymphomas. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003168-35 | Sponsor Protocol Number: IELSG-40 | Start Date*: 2016-08-31 |
Sponsor Name:IELSG International Extranodale Lymphoma Study Group; Instituto Oncologico della Svizzera Italiana, | ||
Full Title: A phase II trial addressing feasibility and activity of clarithromycin + lenalidomide combination: a full oral treatment for patients with relapsed/refractory extranodal marginal zone lymphoma | ||
Medical condition: extranodal marginal zone lymphoma (MALT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003006-32 | Sponsor Protocol Number: ALL2418 | Start Date*: 2019-07-08 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hemato... | ||||||||||||||||||
Medical condition: Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003303-35 | Sponsor Protocol Number: IB2019-04 | Start Date*: 2021-04-08 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||||||||||||
Full Title: Combining epigenetic and immune therapy to beat cancer | ||||||||||||||||||||||||||||||||||||||
Medical condition: | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011454-17 | Sponsor Protocol Number: EPOC-MS-001 | Start Date*: 2010-02-22 |
Sponsor Name:Universitätsklinikum Münster | ||
Full Title: Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia | ||
Medical condition: Acute lymphoblastic leukaemia Ewing sarcoma Neuroblastoma Soft tissue sarcoma Wilms tumours | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003152-33 | Sponsor Protocol Number: MALT-IVA | Start Date*: 2021-02-04 |
Sponsor Name:Med. Univ. Wien | ||
Full Title: A phase II trial of long-term intravenous treatment with bi-weekly Azithromycin in patients with gastric lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma) | ||
Medical condition: gastric MALT Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004596-11 | Sponsor Protocol Number: IELSG 25B | Start Date*: 2005-08-01 |
Sponsor Name:International Extranodal Lymphoma Study Group | ||
Full Title: Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with more than one prior systemic therapy regimen (X05142) | ||
Medical condition: lymphoma of MALT | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-004594-29 | Sponsor Protocol Number: IELSG 25A | Start Date*: 2005-08-01 |
Sponsor Name:International Extranodal Lymphoma Study Group | ||
Full Title: Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142) | ||
Medical condition: lymphoma of MALT | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005790-23 | Sponsor Protocol Number: N/A | Start Date*: 2012-07-17 | ||||||||||||||||||||||||||
Sponsor Name:Birmingham Children's Hospital NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Comparison of adrenal recovery following short and long-term glucocorticoid therapy. | ||||||||||||||||||||||||||||
Medical condition: Adrenal recovery following long and short term steroid treatment. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
